BTOG has now appointed the Steering Committee Trainees: Helen McDill was appointed for Respiratory Trainee Representative and Adam Januszewski was appointed as Oncology Trainee Representative. We received many more applications than we were expecting, and every one was of a … Read More
NICE, the National Institute for Health and Care Excellence, has just published an updated Quality Standard (QS17) for lung cancer in adults. NICE quality standards describe high-priority areas for quality improvement in a defined care or service area. Each standard … Read More
BTOG is excited to be calling for Trainee Representatives from the Oncology and Respiratory specialities to apply to the BTOG Steering Committee. 2 trainee representatives – 1 from each speciality will be appointed to: Act as a point of contact … Read More
September 2019 By Dr Matthew Callister, Consultant Respiratory Physician A year after the preliminary publication of the NELSON screening trial results at the World Conference on Lung Cancer 2018 in Toronto, low-dose CT screening was again headline news in the … Read More
November 2018 By Fiona McDonald, Consultant Thoracic Clinical Oncologist The plenary session at WCLC 2018 in Toronto and parallel NEJM publication bring us the eagerly awaited overall survival results from the PACIFIC trial (NCT02125461). This was a randomised double-blind … Read More
We send a regular newsletter by email to those of our members who subscribe, click here to see the latest issue. Click here to join and subscribe and get your own BTOG E-News in your inbox.
October 2018 By James Spicer, Professor of Experimental Cancer Medicine and Consultant in Medical Oncology ALTA1: brigatinib vs crizotinib in ALK-rearranged non-small cell lung cancer The initial results of this comparison of brigatinib with the first generation drug crizotinib were presented … Read More
September 2018 By Dr Matthew Callister, Consultant Respiratory Physician CT screening in Europe took a leap forward this week with the publication of the mortality results from the NELSON screening study. NELSON was a population-based controlled trial that ran in the … Read More
August 2018 By Tom Newsom-Davis, Consultant Oncologist On 26th July 2018 one of the European Medicines Agency (EMA) committees recommended that the immunotherapy drug, Durvalumab, be licensed for use in patients with locally advanced (stage III) lung cancer. Although this does not mean … Read More